Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 31 December 2019 that Mr Richard Hullihen, the Company’s CEO, has purchased a total of 347,100 ordinary shares of £0.00037
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 31 December 2019 that Mr Richard Hullihen, the Company’s CEO, has purchased a total of 347,100 ordinary shares of £0.00037 (“Ordinary Shares”) via three transactions which are summarised in the table below (the “Transactions”).
| Date of Transaction | Number of Ordinary Shares purchased | Price per Ordinary Share |
| 13 December 2019 | 100,000 | 20.22p |
| 16 December 2019 | 100,000 | 20.02p |
| 27 December 2019 | 147,100 | 23.87p |
Following this Transactions, Mr Hullihen holds a beneficial interest in 2,928,899 Ordinary Shares, representing 2.56 per cent. of the Company’s issued share capital with voting rights.
Enquiries:
| Polarean Imaging plc | ||||
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR | |||
| Richard Morgan, Chairman |
| |||
|
| ||||
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 | |||
| David Hignell / Soltan Tagiev (Corporate Finance) | ||||
| Vadim Alexandre / Rob Rees (Corporate Broking) | ||||
|
| ||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | |||
| Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 | |||